Aemetis, Inc. (NASDAQ:AMTX) Receives $12.95 Consensus Price Target from Brokerages

Shares of Aemetis, Inc. (NASDAQ:AMTX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $12.95.

AMTX has been the topic of a number of research analyst reports. UBS Group reduced their target price on Aemetis from $8.25 to $7.75 and set a "buy" rating on the stock in a report on Monday, August 19th. Ascendiant Capital Markets decreased their price target on shares of Aemetis from $20.00 to $19.00 and set a "buy" rating for the company in a report on Tuesday, September 3rd. Finally, HC Wainwright reiterated a "buy" rating and set a $28.00 price objective on shares of Aemetis in a research note on Friday, November 15th.

Institutional Investors Weigh In On Aemetis

Several hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp raised its position in shares of Aemetis by 36.1% during the third quarter. State Street Corp now owns 699,089 shares of the specialty chemicals company's stock worth $1,608,000 after purchasing an additional 185,304 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Aemetis in the second quarter worth about $306,000. Susquehanna Fundamental Investments LLC increased its position in shares of Aemetis by 287.4% in the second quarter. Susquehanna Fundamental Investments LLC now owns 126,078 shares of the specialty chemicals company's stock worth $379,000 after acquiring an additional 93,536 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Aemetis in the 3rd quarter valued at approximately $177,000. Finally, Geode Capital Management LLC raised its holdings in shares of Aemetis by 7.7% during the third quarter. Geode Capital Management LLC now owns 924,293 shares of the specialty chemicals company's stock worth $2,126,000 after acquiring an additional 66,031 shares in the last quarter. 27.02% of the stock is currently owned by institutional investors.

Aemetis Trading Down 1.0 %

Shares of Aemetis stock traded down $0.03 during trading hours on Thursday, reaching $3.05. 622,250 shares of the company's stock were exchanged, compared to its average volume of 798,329. The firm has a market capitalization of $151.71 million, a price-to-earnings ratio of -1.36 and a beta of 1.35. Aemetis has a 52-week low of $2.10 and a 52-week high of $7.03. The company has a fifty day moving average of $3.28 and a 200-day moving average of $3.03.

Aemetis (NASDAQ:AMTX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.09. The business had revenue of $81.44 million for the quarter, compared to analyst estimates of $77.79 million. During the same period last year, the firm earned ($0.59) earnings per share. On average, equities research analysts anticipate that Aemetis will post -2.02 earnings per share for the current fiscal year.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.